Osteoporosis, which is characterised by reduced bone mineral density (BMD) and an increased risk of fragility fractures, is the result of a complex interaction between environmental factors and genetic variants that confer susceptibility. Heritability studies have shown that BMD and other osteoporosis-related traits such as ultrasound properties of bone, skeletal geometry and bone turnover have significant inheritable components. Although previous linkage and candidate gene studies have provided few replicated loci for osteoporosis, genome-wide association approaches have produced clear and reproducible findings. To date, 20 genome-wide association studies (GWASs) for osteoporosis and related traits have been conducted, identifying dozens of genes. Further meta-analyses of GWAS data and deep resequencing of rare variants will uncover more novel susceptibility loci and ultimately provide possible therapeutic targets for fracture prevention.
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Osteoporosis is a common skeletal disease characterised by low bone mineral density (BMD) and defects in the microarchitecture of bone, with a consequent increase in bone fragility and susceptibility to fracture (Ref. Osteoporosis is a common complex disease caused by the interplay of genetics and environmental factors, with adverse environmental exposures acting on a genetically susceptible individual to produce disease (Ref. 4). Many factors influence the risk of osteoporosis, including diet, physical activity, medication use and coexisting diseases, but one of the most important clinical risk factors is a positive family history, emphasising the importance of genetics in its pathogenesis (Refs 5, 6). The allelic architecture of osteoporosis is likely to be multifactorial, with each imparting a relatively small effect, but their combined effect, as well as their interaction with environmental factors, probably leads to clinical disease (Ref. 7).
In the past decade, much progress has been made in reproducibly identifying genes that 1 influence osteoporosis. Since 2007, we have experienced an acceleration in the identification of osteoporosis loci with the advent of largescale, high-density genome-wide association studies (GWASs). GWASs, in which several hundred thousand to more than a million single-nucleotide polymorphisms (SNPs) are assayed in thousands of individuals, have been successfully used thus far to identify common genetic variants (those with a minor allele frequency greater than ∼5%) that are associated with common human diseases (Ref. 8).
Osteoporosis is defined clinically through the measurement of BMD, which is primarily evaluated by a dual-emission X-ray absorptiometry scan. Other osteoporosis-related phenotypes such as bone geometry and quantitative ultrasonography can also provide information on fracture prediction (Ref. 9) and assessment of the response to osteoporosis treatment (Refs 10, 11).
BMD is a highly heritable trait, with heritability estimates of 0.6-0. 85 This article reviews the results of linkage and association studies for osteoporosis, with particular focus on the new findings revealed by GWASs since 2007, and discusses future directions for the dissection of the genetic determinants of osteoporosis in the post-GWAS era.
Linkage studies
Linkage analysis has long been used to identify disease-associated loci in inherited diseases. This approach relies on the principle of identity by descent combined with phenotypic information to identify loci conferring disease susceptibility. Linkage analysis is a powerful methodology to detect the causative gene in monogenic bone diseases; however, for complex diseases, the identification of susceptibility genes located within the linkage peak region has proved difficult, and the identified loci have not often been replicated for osteoporosis (Ref. 18 
Genome-wide association studies
GWASs represent a powerful and efficient study design for investigating the genetic architecture of complex diseases arising from common basepair variants (Refs 50, 51). GWASs use dense maps of common SNPs (minor allele frequency >∼5%) that cover the human genome to look for allele-frequency differences between cases and controls (diseases study design) or genotype variation, which can explain trait variation (quantitative traits study design). A significant observation in the variant site is taken to indicate that the corresponding region of the genome contains functional DNA-sequence variants that influence the disease or trait in question (Ref. 52) . GWASs have proved to be a powerful approach in screening the susceptibility genes (Fig. 1) . Note that the SNPs from each study are the reported SNPs either near or within the genes; however, they probably do not represent the causal variants.
BMD loci revealed by GWASs JAG1
rs2273061, located near the JAG1 (jagged 1) locus on 20p12.2, showed significant association with spine BMD (P = 5 × 10 , respectively, in the total sample. IL21R is a cytokine receptor that is important to bone biology and has been identified negatively to be correlated with the destruction of cartilage and bone (Ref. 71) .
ALDH7A1
This susceptibility gene was first found to be associated with osteoporotic fractures (OFs) in a case-control GWAS in 700 elderly Chinese Han subjects, with a follow-up replication study in an independent Chinese sample containing 390 cases with hip OFs and 516 controls (Ref. 62) . SNP rs13182402 within the ALDH7A1 (aldehyde dehydrogenase seven family, member A1) gene on chromosome 5q31 was strongly associated with OFs (P = 2.08 × 10 −9
, odds ratio = 2.25). This SNP was confirmed as consistently associated with hip BMD in both Chinese subjects and Caucasians (P = 6.39 × 10 −6 ). The ALDH7A1 gene encodes an enzyme of the acetaldehyde dehydrogenase superfamily, which degrades and detoxifies acetaldehyde generated by alcohol metabolism. Acetaldehyde has been shown to inhibit osteoblast proliferation and to decrease bone formation (Ref. 72) . Another member of the acetaldehyde dehydrogenase family, ALDH2, has also been found to be significantly associated with osteoporosis (Ref. 73 ).
SP7
The SP7 (also known as OSTERIX) locus on 12q13 was first found to be associated with spine BMD (Ref. 65) . Common SNPs near the SP7 region were also associated with total body BMD in a GWAS in children (Ref. 
ADAMTS18 and TGFBR3
These two susceptible genes were identified by a GWAS performed in different ethnic groups (Ref. 63) . One thousand unrelated white US subjects and 1972 subjects from white US pedigrees were genotyped, along with a Chinese hip fracture sample comprising 350 cases and controls, a Chinese BMD sample with 2955 subjects and a Tobago cohort of 908 males of African ancestry as a replication sample. ADAMTS18 (ADAM metallopeptidase with thrombospondin type 1 motif, 18) and TGFBR3 (transforming growth factor, beta receptor III) were significantly associated with BMD variation in the three major ethnic groups. They also provided in silico replication by using publicly available Framingham GWAS data (2953 whites). In addition, ADAMTS18 variants were also found to be associated with hip fracture.
The allele change from T to C of SNP rs16945612 in ADAMTS18 produced a new TEL2 (a member of the E26 transformation-specific family of transcription factors) binding site in ADAMTS18. TEL2 represses two genes, BMP6 and RARa, which are involved in regulating osteoblast differentiation and bone remodelling (Ref. 
Illustration of novel hits revealed by genome-wide association studies for osteoporosis and related traits Expert Reviews in Molecular Medicine © 2011 Cambridge University Press

ZBTB40
SNP rs7524102 in the 1p36 region, previously implicated in the genetic regulation of BMD by linkage analysis in families (Refs 79, 80), was identified as a potential locus for regulation of both hip and spine BMD by a GWAS with a significant association signal (P = 5 × 10 −16 ) (Ref. 55 ). This association was confirmed by other GWASs (Ref. 65, 66, 91 ). In the region, ZBTB40 (zinc finger and BTB domain containing 40), which is located 80 kb downstream from the signal, may be the susceptible gene. ZBTB40 is expressed in bone; however, the function of this gene is as yet unknown and requires more functional studies to elucidate its role in bone physiology.
SOX6
By genotyping 380 000 SNPs in 1000 homogeneous unrelated Caucasians (female n = 501, male n = 499), Liu and colleagues (Ref. 67) performed the first bivariate GWAS of obesity and osteoporosis. SNPs rs297325 and rs4756846 in intron 1 of the SOX6 (sex-determining region Y-box 6) gene were found to be associated with hip BMD in the male subjects. These findings were further validated in the 1370 male subjects of the Framingham Heart Study cohort. The SOX6 locus was also identified as the FN BMD locus by a meta-analysis (Ref. 66) . SOX6 is a member of the SOX gene family and was previously reported to have an important role in both cartilage formation (chondrogenesis) and obesity-related insulin resistance. Animal model studies show that Sox6 single-null mice present mild skeletal abnormalities, and Sox6-knockout mice fetuses die with a severe, generalised chondrodysplasia (Ref. 81 ).
FAM3C and SFRP4
These two loci were identified in a GWAS in Asian populations (Ref. 68) . By genotyping 352 228 SNPs in 8842 subjects and involving eight quantitative traits, this study found that FAM3C (family with sequence similarity 3, member C) and SFRP4 (secreted frizzled-related protein 4) were associated with BMD. A FAM3C SNP rs7776725 on chromosome 7q31 was found to be associated with BMD at the radius (P = 1.0 × 10 −11
), tibia (P = 1.6 × 10 −6
) and heel (P = 1.9 × 10
−10
). The function of FAM3C gene in bone biology is unclear to date. SNP rs1721400, mapping close to SFRP4, on chromosome 7p14 was consistently associated with BMD at the three sites mentioned above (P = 2.2 × 10 
MARK3
The MARK3 (MAP/microtubule affinityregulating kinase 3) gene on chromosome 14q32.3 was significantly associated with total hip BMD (rs2010281, located in intron 1 of MARK3, had a P-value of 1.8 × 10 
MHC region
Styrkarsdottir and colleagues (Ref. 55 ) first found that SNP rs3130340 in the MHC (major histocompatibility complex) region was associated with spine BMD (P = 1.2 × 10 −7 ). The SNP is located downstream of the uncharacterised chromosome 6 open reading frame 10 gene C6orf10. The association significance of this SNP was also confirmed by meta-analysis (Ref. 66 ). The MHC locus on chromosome 6p21 is associated with a number of immune-related diseases; however, the precise mechanism responsible for osteoporosis in this region is unknown.
LRP4, GPR177 and CTNNB1
Three genes, all involved in the Wnt/β-catenin signalling pathway, that is, LRP4 (low-density lipoprotein receptor-related protein 4), GPR177 (G-protein-coupled receptor 177) and CTNNB1 (catenin beta 1), were found to be strongly associated with BMD. This pathway has an essential role in the regulation of bone mass. Two SNPs, rs2306033 and rs7935346, which are within or close to the LRP4 locus at 11p11.2, were found to be associated with hip BMD, but were not genome-wide significant (Ref. 55 ). This association was further studied by a meta- 
MEF2C, CRHR1, DCDC5, FLJ42280 and STARD3NL
These five novel genes were identified with genome-wide significance in a very large-scale meta analysis of five GWASs (Ref. 66) . The meta-analysis identified eight genome-wide significant loci. (In addition to the five genes mentioned above, another three genes -GRP177, CTNNB1 and SOX6 -are described earlier in this paper.) The study also reported eight known loci and four suggestive loci for BMD.
New loci for other osteoporosis-related phenotypes TBC1D8, OSBPL1A and RAP1A
An integration of the GWAS for osteoporosisrelated traits, including BMD, femoral neck-shaft angle (NSA), femoral neck length and narrowneck width (NW), was performed in 7633 Caucasian women and 3657 men (Ref. 61) . SNP rs2278729 located in intron 4 of TBC1D8 (TBC1 domain family, member 8) on chromosome 2q11.2, and SNP rs7227401 located in intron 4 of OSBPL1A (18q11.2, oxysterol-binding proteinlike 1A) were significantly associated with NSA (P = 1.48 × 10 −7 ) and NW (P = 4.22 × 10 −7
) in men. SNP rs494453, located in intron 2 of RAP1A (member of RAS oncogene family) on chromosome 1p13.2, was found to be associated with NW (P = 2.80 × 10 −7 ) in women, and the association became more significant when analysing women and men together (P = 3.6 × 10 
RTP3
A GWAS for FN bone geometry was performed by analysing 379 000 SNPs in 1000 Caucasians and was replicated in 1488 independent Caucasians and 2118 Chinese subjects (Ref. 56) . SNP rs7430431 in the RTP3 (receptor transporter protein 3) gene on chromosome 3p21 was found to be significantly associated with buckling ratio and femoral cortical thickness (CT). Region 3p21 was previously reported to be linked with CT (LOD = 2.19, P = 0.0006) in 3998 subjects from 434 pedigrees (Ref. 85) . RTP3 is a newly identified gene and its function in regulating bone geometry is still not known.
PLCL1
Four SNPs in the PLCL1 (phospholipase C-like 1) gene were found, in a GWAS performed for hip bone size (Ref. 86) , to be associated with hip bone size by testing 380 000 SNPs in 1000 homogeneous unrelated Caucasians. The association evidence of the region was validated both in an independent UK cohort comprising 1216 Caucasian females and in a Chinese sample with 403 females. The study (Ref. 86) also suggested the association of the PLCL1 gene with hip fractures.
Perspectives
The study of common base-pair variants has provided evidence that osteoporosis is determined by a large number of common variants, each imparting a modest effect. To date, several dozen susceptibility genes have been identified. Promising genes with known function, confirmed by CGASs or GWASs, can now be classified into four biological pathways: the vitamin D endocrine pathway (VDR, DBP), the oestrogen endocrine pathway (ESR1, ESR2, CYP19A1), the Wnt-β-catenin signalling pathway (LRP5, SOST, WNT10B, SFRP1, FOXC2, LRP4, GPR177, CTNNB1) and the RANKL-RANK-OPG pathway (TNFSF11, TNFRSF11A, TNFRSF11B). New genes identified by recent GWASs are expected to reveal new biological pathways as their biological functions are carefully explained through functional studies. Although GWASs have proved to be a reliable approach for investigating the genetic basis of osteoporosis, emerging strategies, such as applications of next-generation resequencing technologies, are required to better understand the majority of heritability, which still has to be accounted for despite these advances.
Although the identification of susceptibility genes for osteoporosis by recent GWASs highlights contributions of common variants, their interacting effects have not been well described. However, note that a significant interaction between ESR1, ESR2, IGF-I and osteoporotic fracture (OF) and other phenotypes, including BMD and aspects of FN structure, has been reported in women (Ref. 30) .
Because the above-described GWASs were carried out in different populations with varying sample size, meta-analytic efforts remain an efficient way of combining signals across tens of thousands of genome-wide genotyped individuals, with follow-up genotyping in an equally well-powered sample. This is especially important when the effect of any common variant on osteoporosis risk is small and the statistical power to identify reproducible signals is insufficient in each GWAS. Such studies will yield more insights into this polygenic trait. For example, a recent meta-analysis of five GWASs of BMD with a sample size of 19 195 identified 13 novel loci and confirmed seven known loci (Ref. 66) .
The most useful aspect of GWASs is that they are able to identify entirely novel proteins that previously had no known role in bone disease. The above GWASs have identified many such loci, but an explanation of the exact mechanism whereby they exert their effect has yet to be described in most cases. Thus further functional experiments interrogating these loci are warranted.
It is now apparent that the variance explained by identified SNPs through GWASs is very low. For example, in one study, the top 15 SNPs associated with LS BMD combined explained ∼2.9% of the variance of the phenotype, and the top 10 SNPs associated with FN BMD explained ∼1.9% of the variance (Ref. 66) . Given the high heritability of BMD and the low variance explained by common variants, it is reasonable to assume that there are other sources of variation in the genome that account for this missing heritability.
Rare base-pair variants with a frequency less than 1% are one such source of variation. With the emergence of affordable resequencing technologies, the ability to identify and accurately measure such rare variants is now possible. Rare variants are also more likely to impart large risks for common disease (Ref. 87 91) suggest that the interrogation of rare base-pair variants will lead to important and biologically tractable targets for osteoporosis therapy.
Genetic variation in identified genes might also help us understand whether certain drugs are best suited for individuals with a certain genotype through pharmacogenetic studies. Although such studies are still in their infancy, they hold promise for identification of groups of individuals better suited for particular interventions. Furthermore, studies might now be undertaken to understand whether the side effects of osteoporosis therapies can be assigned to individuals harbouring certain genotypes. These two avenues of research provide potential ways of improving osteoporosis patient care through genetic information.
The final aim of genetic studies, such as those described above, is much more than the identification of susceptibility variants. First, identified genes will provide therapeutic targets after thorough functional studies. Second, efforts are also required to understand whether information on genotype profile can improve the prediction of OF risk. However, the small effects identified by GWASs arising from common variants suggest that the second aim will be difficult to fulfil. Although these studies are ongoing, the description of a large set of common base-pair variants reproducibly associated with osteoporosis represents a large step forward in understanding the genetic and biological basis of this disease.
Since submission of this manuscript, two additional GWASs have been published. Duncan Figure  Figure 1 . Illustration of novel hits revealed by genome-wide association studies for osteoporosis and related traits. Table  Table 1 . Promising candidate genes in osteoporosis.
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